Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4871MR)

This product GTTS-WQ4871MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4871MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2350MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AME-133v
GTTS-WQ4292MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ2498MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ5316MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ4130MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ13272MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ9767MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ6087MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW